國立高雄大學圖資館 |

語系: 繁體中文

說明(常見問題)

圖資館首頁

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Drug treatment of sleep disorders

Guglietta, Antonio.

Drug treatment of sleep disorders

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Drug treatment of sleep disordersedited by Antonio Guglietta.
其他作者:	Guglietta, Antonio.
出版者:	Cham :Springer International Publishing :2015.
面頁冊數:	viii, 297 p. :ill., digital ;24 cm.
Contained By:	Springer eBooks
標題:	Sleep disordersChemotherapy.
電子資源:	http://dx.doi.org/10.1007/978-3-319-11514-6
ISBN:	9783319115146 (electronic bk.)

Drug treatment of sleep disorders
Drug treatment of sleep disorders[electronic resource] /edited by Antonio Guglietta. - Cham :Springer International Publishing :2015. - viii, 297 p. :ill., digital ;24 cm. - Milestones in drug therapy,2296-6056. - Milestones in drug therapy..

An overview of sleep physiology and sleep regulation -- Neuronal networks regulating sleep and arousal: effect of drugs -- Classification of sleep disorders -- Development of new therapeutical agents for treatment of insomnia and other sleep disorders -- Low dose doxepin for insomnia -- Lorediplon: a new GABAa modulator drug for treatment of insomnia -- Zolpidem sublingual formulations -- Eszopiclone: review and clinical applications in chronic and co-morbid insomnia -- Orexin/hypocretin antagonists in insomnia: from bench to clinic -- Modafinil and armodafinil -- Sodium oxybate (Xyrem): a new and effective treatment for narcolepsy with cataplexy -- Cell therapy to treat narcolepsy -- Tasimelteon -- The past, present and future of drug development and treatment in sleep disorders.

Following reviews on sleep physiology, regulation, pharmacology, and the neuronal networks regulating sleep and awakening, as well as a classification of sleep disorders, this book presents a number of major breakthroughs in the treatment of those disorders. These include recently approved drugs for treating insomnia, such as Doxepin; variations on previously approved molecules, e.g. Zolpidem sublingual preparation; or new chemical entities in advanced stages of clinical development, e.g. Orexin antagonists. Further topics discussed include drugs acting on the GABA receptor, such as Lorediplon and Eszopiclone; the treatment of excessive daytime drowsiness with cell therapy and drugs such as Modafinil, Armodafinil and Sodium oxybate; and the use of Tasimelteon in the treatment of circadian sleep disorders.

ISBN: 9783319115146 (electronic bk.)

Standard No.: 10.1007/978-3-319-11514-6doiSubjects--Topical Terms:

711707
Sleep disorders
--Chemotherapy.

LC Class. No.: RC547

Dewey Class. No.: 616.8498061

Drug treatment of sleep disorders
LDR:02588nmm a2200325 a 4500 001 460339
003 DE-He213
005 20150629165837.0
006 m d
007 cr nn 008maaau
008 151110s2015 gw s 0 eng d
020 $a 9783319115146 (electronic bk.)
020 $a 9783319115139 (paper)
024 7 $a 10.1007/978-3-319-11514-6 $2 doi
035 $a 978-3-319-11514-6
040 $a GP $c GP
041 0 $a eng
050 4 $a RC547
072 7 $a MMG $2 bicssc
072 7 $a MED071000 $2 bisacsh
082 0 4 $a 616.8498061 $2 23
090 $a RC547 $b .D794 2015
245 0 0 $a Drug treatment of sleep disorders $h [electronic resource] / $c edited by Antonio Guglietta.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2015.
300 $a viii, 297 p. : $b ill., digital ; $c 24 cm.
490 1 $a Milestones in drug therapy, $x 2296-6056
505 0 $a An overview of sleep physiology and sleep regulation -- Neuronal networks regulating sleep and arousal: effect of drugs -- Classification of sleep disorders -- Development of new therapeutical agents for treatment of insomnia and other sleep disorders -- Low dose doxepin for insomnia -- Lorediplon: a new GABAa modulator drug for treatment of insomnia -- Zolpidem sublingual formulations -- Eszopiclone: review and clinical applications in chronic and co-morbid insomnia -- Orexin/hypocretin antagonists in insomnia: from bench to clinic -- Modafinil and armodafinil -- Sodium oxybate (Xyrem): a new and effective treatment for narcolepsy with cataplexy -- Cell therapy to treat narcolepsy -- Tasimelteon -- The past, present and future of drug development and treatment in sleep disorders.
520 $a Following reviews on sleep physiology, regulation, pharmacology, and the neuronal networks regulating sleep and awakening, as well as a classification of sleep disorders, this book presents a number of major breakthroughs in the treatment of those disorders. These include recently approved drugs for treating insomnia, such as Doxepin; variations on previously approved molecules, e.g. Zolpidem sublingual preparation; or new chemical entities in advanced stages of clinical development, e.g. Orexin antagonists. Further topics discussed include drugs acting on the GABA receptor, such as Lorediplon and Eszopiclone; the treatment of excessive daytime drowsiness with cell therapy and drugs such as Modafinil, Armodafinil and Sodium oxybate; and the use of Tasimelteon in the treatment of circadian sleep disorders.
650 0 $a Sleep disorders $x Chemotherapy. $3 711707
650 1 4 $a Biomedicine. $3 273648
650 2 4 $a Pharmacology/Toxicology. $3 273652
650 2 4 $a Neurosciences. $3 211508
650 2 4 $a Pharmacotherapy. $3 615025
650 2 4 $a Psychopharmacology. $3 252258
700 1 $a Guglietta, Antonio. $3 711706
710 2 $a SpringerLink (Online service) $3 273601
773 0 $t Springer eBooks
830 0 $a Milestones in drug therapy. $3 557479
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-11514-6
950 $a Biomedical and Life Sciences (Springer-11642)